Investors Grow Wary of Big Pharma Shares as Earnings Season Unfolds
According to Market Talk, citing RBC Capital Markets, investors are becoming more cautious on large drugmakers' stocks during the third-quarter reporting season.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Market Talk, citing a sector research note from RBC Capital Markets, reports that investors are growing more cautious about large pharmaceutical shares as third-quarter results come in. The bank's analysts argue that the recent sector rally reflects capital rotating in from other industries rather than the appeal of the pharma business itself. In their view, the weak market reaction to Johnson & Johnson's sound report last week points to greater fragility in the group.
why it matters
Health care is viewed as a defensive sector, so shifts in sentiment there affect capital rotation between industries and the Stoxx Europe 600 Health Care index, which gained 0.6%. RBC expects strong figures from Eli Lilly but sees pricing pressure as a risk. For Roche and AbbVie, in-line numbers may not be enough, while for AstraZeneca and Bristol Myers Squibb, comments on upcoming clinical trials could matter more than earnings. The reports will show how far the sector's recent gains are backed by fundamentals.
market impact
Pharma sector: investor caution and pricing risks could weigh on large European drugmakers' shares
instruments
sources
- Investors Are Turning Cautious on Big Pharma as Earnings Season Unfolds — Market Talk, 20 October 2026 at 07:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗